Entry Detail



General Information

Database ID:exR0093207
RNA Name:hsa-miR-191-5p
RNA Type:miRNA
Chromosome:chr3
Starnd:-
Coordinate:
Start Site(bp):49020672End Site(bp):49020694
External Links:hsa-miR-191-5p



Disease Information

Disease Name:Benign Ovarian Disease
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D010049
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Ovarian Diseases//Disease, Ovarian//Diseases, Ovarian//Ovarian Disease



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Benign Ovarian Disease
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:NA
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001186
chr21
35475133
35475818
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC079781.5
chr7
97851688
97972985
-
MIR503HG
chrX
134543119
134546642
-
RRN3P2
chr16
29074976
29116718
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.